| |
Evaluation of Cardiovascular Disease (CVD) Risk in HIV-1-infected Patients Treated With Darunavir/Ritonavir (DRV/r)
|
| |
| |
"A recent observational study examined the association between CVD risk and use of 2 contemporary PIs, DRV/r and atazanavir (ATV)/r 6 - 6. Ryom L, et al. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 13-16, 2017; Seattle, WA. Oral abstract 128LB."
Reported by Jules Levin
presented at the 11th Annual American Conference for the Treatment of HIV (ACTHIV); April 20-22, 2017; Dallas, Texas.
Magda Opsomer,1 Dessislava Dimitrova,2 Johan Verspeelt,1 Amy Purrington,3 Scott Chavers,2 Helen Pai,4 Simon Vanveggel,1 Donghan Luo,2 Kimberley Brown,5,* Christiane Moecklinghoff,6 Richard Nettles,5 Katia Boven2
1Janssen Research & Development, Beerse, Belgium; 2Janssen Research & Development, LLC, Titusville, NJ, USA; 3Janssen Research & Development, LLC, Horsham, PA, USA; 4Janssen Research & Development, LLC, Raritan, NJ, USA; 5Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 6Janssen EMEA, Neuss, Germany.
|
|
| |
| |
|
|
|
